Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$14,999.40
Sep 13, 2024
For-profit organization
FR-27045
FR-27045
Develop digital adoption plan
$29,900.00
Sep 10, 2024
Academia
North Shore Walleye Telemetry
GC-2676
This grant supports a telemetry research project focused on the quantifying connectivity, movement patterns, and gene flow of Walleye across the north shore of Lake Superior.
$204,387.00
Sep 5, 2024
Not-for-profit organization or charity
Non-Viral Gene Therapy for Myotubular Myopathy: Skeletal Muscle Targeted
Lipid Nanoparticle-Mediated Delivery of the MTM1 Gene to Restore Muscle
Function.
1025235
Myotubular myopathy is a severe congenital disorder marked by muscle
weakness and hypotonia due to mutations in the MTM1 gene, which encodes
myotubularin. This protein is crucial for muscle cell maintenance and repair, and
its deficiency disrupts these processes, causing significant muscle dysfunction.
Current treatments are symptomatic and fail to address the genetic cause,
necessitating therapies that target the root of the disease. Gene therapy,
particularly with viral vectors, shows promise but has limitations such as immune
responses and high costs. Recent safety setbacks in AAV8-MTM1 gene therapy
trials underscore the need for alternative delivery methods.
$30,000.00
Sep 2, 2024
For-profit organization
Bio Data Scientists
1022113
The project aims to hire a Bio Data scientist to optimize the manufacturing processes for cell and gene therapy by identifying the optimal production conditions.
$29,670.00
Aug 29, 2024
Not-for-profit organization or charity
Contribution to International Charity Foundation Music for All
CFLI-2024-KYIV-UA-0003
Music therapy and psycho-emotional rehabilitation for recovering Ukrainian defenders.
$15,000.00
Jul 19, 2024
For-profit organization
FR-30934
FR-30934
Develop digital adoption plan
$75,000.00
Jul 1, 2024
For-profit organization
Analytics Development to Support Production of CAR-T Cell Therapy
1020634
Development of a qPCR method for CD19 CAR Gene Expression and Vector Copy Number (VCN)
3.
$225,000.00
Jul 1, 2024
For-profit organization
Development of a High Pressure Storage Solution for Cell Gene Therapy Applications
1022481
Develop a high pressure system for use in Cell Gene Therapy applications.
$2,128.00
Jun 24, 2024
For-profit organization
Little River Holistic Therapies
019545813
Through the application of national and local priorities, the CSJ program seeks to provide youth, particularly those who face barriers to employment with access to work opportunities. Funded employers must demonstrate that they are providing quality work experiences for youth that provide opportunities to develop and improve their skills.
$1,050,000.00
Jun 24, 2024
For-profit organization
1018196
1018196
To enhance manufacturing capabilities and laboratory units at its new viral vector facility.